chartexchange

IBRX270115P00009000
IBRX Jan 15 2027 9.00 Put
optionOPRA

EODOct 16, 2026
1.62USD+5.882%(+0.09)72Vol52,470OI
Loading…
Underlying
Underlying Price
$8.48
Type
Put
Strike
9
Expiration
Jan 15, 2027
DTE
87d
Moneyness
ITM
Intrinsic
$0.52
IBRX 9 Put Across Expirations
ExpirationDTELastChangeVolOpen Int
Oct 23, 20263d$0.37+48.00%175792
Oct 30, 202610d$0.50+72.41%53555
Nov 6, 202617d$0.49+2.08%140
Nov 13, 202624d$0.75+25.00%4232
Nov 20, 202631d$0.90+21.62%651,550
Nov 27, 202638d$1.02+20.00%25
Dec 18, 202659d$1.15+0.00%405405
Jan 15, 202787d$1.62+5.88%7252,470
Mar 19, 2027150d$1.84-10.68%20137
Apr 16, 2027178d$2.45+22.50%1025
May 21, 2027213d$2.35+0.00%6060
IBRX Nearby Strikes · Jan 15, 2027
StrikeLastChangeVolOpen IntMoneyness
3.5 P$0.12+20.00%21,305OTM
4 P$0.20+0.00%80272OTM
4.5 P$0.20+25.00%20439OTM
5 P$0.29+3.57%1724,922OTM
5.5 P$0.30-14.29%3033,349OTM
7.5 P$0.90+20.00%12122,697OTM
9 P$1.62+5.88%7252,470ITM
10 P$2.06+1.48%506,506ITM
11 P$2.65-7.02%7150ITM
12 P$3.30-10.81%4881ITM
13 P$4.70+14.63%26ITM
14 P$4.80-9.60%2024ITM
15 P$7.70+21.84%1503ITM
IBRX Profile

immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.